ANRO – alto neuroscience, inc. (US:NASDAQ)
Stock Stats
News
Alto Neuroscience Starts Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Alto Neuroscience (ANRO) had its price target lowered by Robert W. Baird from $41.00 to $38.00. They now have an "outperform" rating on the stock.
Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Form EFFECT Alto Neuroscience, Inc.
Form S-3 Alto Neuroscience, Inc.
Form 8-K Alto Neuroscience, Inc. For: Apr 01
Form ARS Alto Neuroscience, Inc. For: Dec 31
Form DEFA14A Alto Neuroscience, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.